ATOS trade ideas
XABCD props for price movement $63 by 2023 or $24?Couple of propositions here based on XABCD price movement patterrns forming on monthly. The paths are many, price can be any one space at any time but this looks to be on floor 0 with many levels above. I like option 2 - $63 by 2023. Let's see how it plays out
TIME AND SPACE: MONTHLY IMPLIES 15+ ON THE CARDSGEOMETRICS implies 15-30 has been on the cards for sometime now. Once the price can escape old movement dynamics ATOS can rise 10 fold
ATOS will she retrace?Few things i noticed:
Volume is thinning out
MACD is curling
ADX higher highs is lower than the former and heading downwards.
DI+ crossed over ADX.
However, StochRSI says its oversold
Fundamentally it is driven by the following reasons:
Has COVID19 Drug candidate.
Low FLOAT: 9.8M shares.
Based from these indicators, I suspect that the best entry is either at SMA20 and the safest is at .382 or .5 retracement. However, it must be confirmed some if no all several indicators:
1. StochRSI,
2. ADX or DI
3. MACD
I do not see any near term catalyst for ATOS so far but if I do I will add in the updates. I have yet to read all the 8Ks
$ATOS can rise in the next daysContextual immersion trading strategy idea.
Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States.
The share price rose after announcing the availability of the CEO's 158-page book "Your COVID-19 Survival Manual: A Physician's Guide to Keep You and Your Family Healthy During the Pandemic and Beyond"
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $3,21;
stop-loss — $3,08.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
$ATOS can rise in the next daysContextual immersion trading strategy idea.
The demand for shares of Atossa Therapeutics looks higher than the supply.
The company develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions.
Due to the spread of COVID-19, the demand for the company`s services rose.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $1,58;
stop-loss — $1,50.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
ATOS Bullish Signals ATOS Short Term Prediction. Spotted Cup & Handle for ATOS. The RSI dipped below 50 with MACD histogram showing good progress of moving towards the 0 line. Entry in the 1.50’s is a good buy before it jumps above 2$ within a week or two.
Atossa Genetics Announces Phase 2 Study Contract for Oral EndoxiATOS: Atossa Genetics Inc.
2019-12-19 08:30:10
Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women
$ATOS Is A Good Risk/Reward PlayAbout Atossa Genetics
Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.
Atossa Genetics is making moves!!Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density
This is what we are looking for, go long with this CV company. Find a good entry point and squat!! If FDA approved this will go back where it cam from $$$
$ATOS Speculation in Atossa Genetics continues pre 25th April.The rumor mill continues to spin in ATOS prior to a presentation scheduled for April the 25th, the spike in volume hopefully preempts a positive move. Keep it on the watchlist.
ATOSSA Good news for women's and investorAtossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, yesterday FDA Aprroved Oral Endoxifen for breast cancer patient.
Endoxifen is an active metabolite of tamoxifen, which is an FDA-approved drug to prevent new as well as recurrent disease in breast cancer patients.
This good news bring positive impact to Atossa stocks.
Yesterday Atossa rose 395.26%, and this price movement is nothing if we compare with monthly range at past few years.
For long term investment, We have 24000% profit projection at 128.75 and 90000% maximum profit projection at 479
ATOSSA financial strength :
Piotroski F-Score: 3
Altman Z-Score: -7.74
Beneish M-Score: -4.78
Cash to debt : 0
atos longlook for a long after breaking of trend and pull back to the level it broke up, if this level holds should be good indication of going up to the next levels.
ATOS Recent Reverse SplitDon't have time to lay out the details. Recent squeeze, warrants didnt get exercised either. Chance that this next squeeze will follow through with an offering
SHORT TERM TRADE
ATOS Bullish MACD Divergence, Possible Buy SignalYesturday marked a possible buy signal. The price action is making newer lows, while the MACD is making higher highs, this marks a bullish divergence. Tomorrow should be the confirmation of this signal, if and only if this it closes higher than todays close.
